Cellecta’s primary aim is to develop advanced high-throughput RNAi and CRISPR technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
Cellecta’s primary aim is to develop advanced high-throughput RNAi and CRISPR technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
Location:
320 Logue Ave. Mountain View, CA 94043 USA
Categories:
The Synthetic Genome
Founded in:
2006
Employee number:
10-100
Annual revenue:
$5.5M